- Home
- BCG vs NRSN Comparison
BCG vs NRSN Comparison
Compare BCG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | NRSN |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Israel |
| Employees | 150 | 16 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7M | 25.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BCG | NRSN |
|---|---|---|
| Price | $1.48 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 27.4K | ★ 119.5K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.36 | $0.63 |
| 52 Week High | $3.44 | $2.52 |
Technical Indicators
Market Signals| Indicator | BCG | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 49.90 |
| Support Level | $1.52 | $0.67 |
| Resistance Level | $2.49 | $0.86 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 20.01 | 50.10 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.